SS Innovations submits FDA response with final data from expanded SSi Mantra clinical, human factors study
SS Innovations submitted its response on Oct. 5, 2026 to an FDA request tied to its SSi Mantra 510(k) filing. Results have already been provided to the FDA, including final data from an expanded human clinical and human-factors validation study. The submission also included final data from a bridging study completed in